Salt AI, a company specializing in contextual artificial intelligence for the life sciences and health tech industries, has announced a $10 million funding round. The investment was led by Morpheus Ventures, with additional support from Struck Capital, Marbruck Investments, and CoreWeave.
This funding will help Salt AI grow its customer base among biopharmaceutical and healthcare organizations that are actively investing in advanced AI technologies. It will also enable the company to scale its global engineering teams, thereby accelerating development and enhancing the impact of its platform.
Salt AI’s platform is designed to make enterprise AI more transparent and accessible. Many organizations struggle with the complexity and opacity of traditional AI systems, often referred to as “black boxes.” Salt AI addresses this by offering a visual-first interface that still supports full coding capabilities. This enables teams to build, deploy, and manage AI-powered workflows across various business functions—from drug discovery and clinical trials to revenue cycle management and data navigation.
One example of Salt AI’s impact can be seen at the Ellison Medical Institute, where the platform has been used to accelerate research in computational biology. Since mid-2024, EMI has used Salt AI to design and analyze thousands of chemical compounds, leading to the advancement of two promising protein candidates into more detailed laboratory studies. The platform’s flexible workflows allow researchers to continuously refine their digital design process, making it easier to move from concept to experimentation.
Central to Salt AI’s technology is the Salt Matrix, a catalog of specialized data connectors, models, and tools tailored to the needs of life sciences and healthcare teams. Users can build AI workflows quickly using drag-and-drop features, which simplifies collaboration between scientists, engineers, and business leaders. The platform is built around three core strengths: enabling real-time collaboration across disciplines, delivering fast results through rapid deployment in private or on-premise environments, and maintaining strict compliance standards for enterprise-level adoption.
With this new funding, Salt AI is well-positioned to deepen its role in transforming how healthcare and biotech companies utilize AI, enabling them to unlock faster innovation and more efficient operations across the board.
KEY QUOTES:
“Salt AI is the kind of company CoreWeave aims to support, applying AI to one of society’s most urgent challenges. Our AI cloud platform is purpose-built for complex models, enabling Salt Ai to run workloads quickly and reliably and giving life sciences companies a practical way to integrate AI into everyday research.”
Brian Venturo, Co-founder and Chief Strategy Officer, CoreWeave
“We are in the midst of a breakthrough moment in life sciences, with AI igniting unprecedented opportunities that were once out of reach. No single AI model can unlock the future of medicine alone. The future belongs to ensembles, models working in synergy. At Salt AI, our platform is designed so organizations can rapidly create, launch, and scale AI solutions that drive healthcare innovation forward. We’re proud that a growing roster of major enterprises already relies on us to reach new milestones in discovery and improve real-world outcomes across the industry.”
Aber Whitcomb, CEO and Co-Founder of Salt AI
“Salt AI represents a transformative advance in the computational biology stack. By combining drag‑and‑drop workflows with transparent AI integration, the platform enables a new paradigm of therapeutic design, one that is faster, more efficient, and highly data-driven.”
Dr. David Agus, Founding CEO of the Ellison Medical Institute
